Fig. 3

The diagnostic significance of ADAM6 and PRSS1 using ROC analysis. A ROC curves for discrimination between acute leukemia patients and healthy control subjects using ADAM6 or PRSS1. ADAM6 showed excellent diagnostic value (AUC = 1, sensitivity = 100%, specificity = 100%, cutoff criterion > 123.8 pg/ml and 95% CI (0.972–1), while PRSS1 ROC curve showed good diagnostic value (AUC = 0.79, sensitivity = 73.68%, specificity = 74.5%, cutoff criterion < 207.6 ng/ml and 95% CI (0.707—0.854)). B ROC curves for discrimination between ALL patients and healthy control subjects using ADAM6 or PRSS1. ROC curve for ADAM6 showed excellent diagnostic value (AUC = 1, sensitivity = 100%, specificity = 100%, cutoff criterion > 123.76 pg/ml and 95% CI (0.972–1)), while PRSS1 showed good diagnostic value (AUC = 0.752, sensitivity = 69%, specificity = 73%, cutoff criterion < 214.44 ng/ml and 95%CI (0.651–837)). C ROC curves for discrimination between AML patients and healthy control subjects using ADAM6 or PRSS1. ROC curve for ADAM6 showed excellent diagnostic value (AUC = 1, sensitivity = 100%, specificity = 100%, cutoff criterion > 123.8 pg/mL and 95% CI (0.962–1)), while ROC curve for PRSS1 showed very good diagnostic value (AUC = 0.819, sensitivity = 80%, specificity = 74.5%, cutoff criterion < 207.6 ng/mL and 95% CI (0.727—0.890)). ROC, receiver operator characteristic curve; AUC, area under the curve; CI, confidence interval; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; PRSS1, Serine protease 1; and ADAM6, A Disintegrin And Metalloproteinase Domain-6